Annual FCF
-$92.72 M
+$56.95 M+38.05%
December 31, 2023
Summary
- As of February 8, 2025, KPTI annual free cash flow is -$92.72 million, with the most recent change of +$56.95 million (+38.05%) on December 31, 2023.
- During the last 3 years, KPTI annual FCF has risen by +$67.66 million (+42.19%).
- KPTI annual FCF is now -938.91% below its all-time high of -$8.93 million, reached on December 31, 2011.
Performance
KPTI Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$19.45 M
+$19.05 M+49.47%
September 30, 2024
Summary
- As of February 8, 2025, KPTI quarterly free cash flow is -$19.45 million, with the most recent change of +$19.05 million (+49.47%) on September 30, 2024.
- Over the past year, KPTI quarterly FCF has increased by +$19.05 million (+49.47%).
- KPTI quarterly FCF is now -175.49% below its all-time high of $25.77 million, reached on December 31, 2021.
Performance
KPTI Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$120.46 M
+$10.08 M+7.72%
September 30, 2024
Summary
- As of February 8, 2025, KPTI TTM free cash flow is -$120.46 million, with the most recent change of +$10.08 million (+7.72%) on September 30, 2024.
- Over the past year, KPTI TTM FCF has increased by +$10.08 million (+7.72%).
- KPTI TTM FCF is now -2235.78% below its all-time high of -$5.16 million, reached on March 31, 2013.
Performance
KPTI TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
KPTI Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +38.0% | +49.5% | +7.7% |
| 3 y3 years | +42.2% | +35.1% | +28.9% |
| 5 y5 years | +42.6% | +46.9% | +36.9% |
KPTI Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +38.0% | -175.5% | +67.2% | -29.9% | +19.5% |
| 5 y | 5-year | at high | +51.5% | -175.5% | +67.2% | -29.9% | +36.9% |
| alltime | all time | -938.9% | +51.5% | -175.5% | +70.8% | -2235.8% | +40.8% |
Karyopharm Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$19.45 M(-49.5%) | -$120.46 M(-7.7%) |
| Jun 2024 | - | -$38.50 M(-12.3%) | -$130.53 M(+10.9%) |
| Mar 2024 | - | -$43.92 M(+136.3%) | -$117.73 M(+27.0%) |
| Dec 2023 | -$92.72 M(-38.0%) | -$18.59 M(-37.1%) | -$92.72 M(-8.2%) |
| Sep 2023 | - | -$29.53 M(+14.9%) | -$100.98 M(+1.1%) |
| Jun 2023 | - | -$25.70 M(+35.9%) | -$99.86 M(-8.6%) |
| Mar 2023 | - | -$18.91 M(-29.6%) | -$109.31 M(-27.0%) |
| Dec 2022 | -$149.67 M(+32.7%) | -$26.84 M(-5.5%) | -$149.67 M(+54.2%) |
| Sep 2022 | - | -$28.41 M(-19.2%) | -$97.06 M(-1.6%) |
| Jun 2022 | - | -$35.14 M(-40.7%) | -$98.61 M(-17.3%) |
| Mar 2022 | - | -$59.28 M(-330.0%) | -$119.22 M(+5.7%) |
| Dec 2021 | -$112.83 M(-29.6%) | $25.77 M(-186.0%) | -$112.83 M(-33.4%) |
| Sep 2021 | - | -$29.96 M(-46.3%) | -$169.35 M(-7.8%) |
| Jun 2021 | - | -$55.75 M(+5.4%) | -$183.70 M(+9.2%) |
| Mar 2021 | - | -$52.89 M(+72.0%) | -$168.25 M(+4.9%) |
| Dec 2020 | -$160.38 M(-16.0%) | -$30.75 M(-30.6%) | -$160.38 M(-5.2%) |
| Sep 2020 | - | -$44.31 M(+10.0%) | -$169.16 M(+4.8%) |
| Jun 2020 | - | -$40.29 M(-10.5%) | -$161.47 M(-4.7%) |
| Mar 2020 | - | -$45.02 M(+13.9%) | -$169.38 M(-11.3%) |
| Dec 2019 | -$191.03 M(+18.3%) | -$39.54 M(+8.0%) | -$191.03 M(-4.8%) |
| Sep 2019 | - | -$36.61 M(-24.0%) | -$200.75 M(-1.3%) |
| Jun 2019 | - | -$48.20 M(-27.7%) | -$203.30 M(+5.3%) |
| Mar 2019 | - | -$66.67 M(+35.3%) | -$193.12 M(+19.6%) |
| Dec 2018 | -$161.48 M | -$49.27 M(+25.8%) | -$161.48 M(+37.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$39.16 M(+3.0%) | -$117.81 M(+17.3%) |
| Jun 2018 | - | -$38.02 M(+8.5%) | -$100.41 M(+19.4%) |
| Mar 2018 | - | -$35.03 M(+526.4%) | -$84.11 M(+14.0%) |
| Dec 2017 | -$73.78 M(-12.6%) | -$5.59 M(-74.3%) | -$73.78 M(-16.4%) |
| Sep 2017 | - | -$21.76 M(+0.2%) | -$88.21 M(+1.6%) |
| Jun 2017 | - | -$21.72 M(-12.1%) | -$86.79 M(+1.0%) |
| Mar 2017 | - | -$24.71 M(+23.4%) | -$85.97 M(+1.8%) |
| Dec 2016 | -$84.46 M(-11.5%) | -$20.02 M(-1.5%) | -$84.46 M(-1.0%) |
| Sep 2016 | - | -$20.33 M(-2.7%) | -$85.32 M(-5.7%) |
| Jun 2016 | - | -$20.90 M(-9.9%) | -$90.45 M(-7.9%) |
| Mar 2016 | - | -$23.20 M(+11.1%) | -$98.25 M(+2.9%) |
| Dec 2015 | -$95.44 M(+75.8%) | -$20.88 M(-18.0%) | -$95.44 M(+9.2%) |
| Sep 2015 | - | -$25.47 M(-11.2%) | -$87.43 M(+8.6%) |
| Jun 2015 | - | -$28.70 M(+40.6%) | -$80.48 M(+25.8%) |
| Mar 2015 | - | -$20.40 M(+58.6%) | -$63.99 M(+17.9%) |
| Dec 2014 | -$54.28 M(+78.9%) | -$12.87 M(-30.5%) | -$54.28 M(+5.3%) |
| Sep 2014 | - | -$18.52 M(+51.7%) | -$51.52 M(+22.9%) |
| Jun 2014 | - | -$12.21 M(+14.1%) | -$41.93 M(+16.9%) |
| Mar 2014 | - | -$10.69 M(+5.8%) | -$35.88 M(+18.2%) |
| Dec 2013 | -$30.35 M(+94.2%) | -$10.11 M(+13.3%) | -$30.35 M(+50.0%) |
| Sep 2013 | - | -$8.92 M(+45.0%) | -$20.24 M(+78.9%) |
| Jun 2013 | - | -$6.16 M(+19.4%) | -$11.31 M(+119.4%) |
| Mar 2013 | - | -$5.16 M | -$5.16 M |
| Dec 2012 | -$15.63 M(+75.1%) | - | - |
| Dec 2011 | -$8.93 M | - | - |
FAQ
- What is Karyopharm Therapeutics annual free cash flow?
- What is the all time high annual FCF for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics annual FCF year-on-year change?
- What is Karyopharm Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics quarterly FCF year-on-year change?
- What is Karyopharm Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Karyopharm Therapeutics?
- What is Karyopharm Therapeutics TTM FCF year-on-year change?
What is Karyopharm Therapeutics annual free cash flow?
The current annual FCF of KPTI is -$92.72 M
What is the all time high annual FCF for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high annual free cash flow is -$8.93 M
What is Karyopharm Therapeutics annual FCF year-on-year change?
Over the past year, KPTI annual free cash flow has changed by +$56.95 M (+38.05%)
What is Karyopharm Therapeutics quarterly free cash flow?
The current quarterly FCF of KPTI is -$19.45 M
What is the all time high quarterly FCF for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high quarterly free cash flow is $25.77 M
What is Karyopharm Therapeutics quarterly FCF year-on-year change?
Over the past year, KPTI quarterly free cash flow has changed by +$19.05 M (+49.47%)
What is Karyopharm Therapeutics TTM free cash flow?
The current TTM FCF of KPTI is -$120.46 M
What is the all time high TTM FCF for Karyopharm Therapeutics?
Karyopharm Therapeutics all-time high TTM free cash flow is -$5.16 M
What is Karyopharm Therapeutics TTM FCF year-on-year change?
Over the past year, KPTI TTM free cash flow has changed by +$10.08 M (+7.72%)